olanzapine sold trade name zyprexa among others atypical antipsychotic primarily used treat schizophrenia bipolar schizophrenia used newonset disease longterm taken mouth injection common side effects include weight gain movement disorders dizziness feeling tired constipation dry side effects include low blood pressure standing allergic reactions neuroleptic malignant syndrome high blood sugar seizures tardive older people dementia use increases risk use later part pregnancy may result movement disorder baby time although works entirely clear blocks dopamine serotonin olanzapine patented approved medical use united states available generic commonly prescribed medication united states million eli lilly also markets olanzapine fixeddose combination fluoxetine olanzapinefluoxetine world health organizations list essential approved fda following indications united kingdom australia approved schizophrenia moderate severe manic episodes alone combination lithium valproate shortterm treatment acute manic episodes associated bipolar firstline psychiatric treatment schizophrenia antipsychotic olanzapine appears effective reducing symptoms schizophrenia treating acute exacerbations treating earlyonset usefulness maintenance therapy however difficult determine half people trials quit completion treatment olanzapine like clozapine may result increased weight gain increased glucose cholesterol levels compared secondgeneration antipsychotic drugs used treat olanzapine recommended national institute health care excellence firstline therapy treatment acute mania bipolar recommended firstline treatments aripiprazole haloperidol quetiapine recommended combination fluoxetine firstline therapy acute bipolar depression secondline treatment maintenance treatment bipolar network mood anxiety treatments recommends olanzapine firstline maintenance treatment bipolar disorder combination olanzapine fluoxetine secondline treatment bipolar review efficacy olanzapine maintenance therapy patients bipolar disorder published dando tohen metaanalysis concluded olanzapine fluoxetine effective among nine treatments bipolar depression included olanzapine may useful promoting weight gain underweight adult outpatients anorexia nervosa however improvement psychological symptoms olanzapine shown helpful addressing range anxiety depressive symptoms individuals schizophrenia schizoaffective disorders since used treatment range mood anxiety olanzapine less effective lithium valproate effective placebo treating bipolar also used tourette syndrome olanzapine studied treatment hyperactivity aggressive behavior repetitive behaviors olanzapine frequently prescribed offlabel treatment insomnia including difficulty falling asleep staying asleep even though use daytime sedation experienced olanzapine generally comparable quetiapine lurasidone frequent complaint clinical trials cases sedation due olanzapine impaired ability people wake consistent time every day evidence efficacy treating insomnia seen however side effects dyslipidemia neutropenia may possibly observed even low doses outweigh potential benefits insomnia due underlying mental health olanzapine recommended used antiemetic regimens people receiving chemotherapy high risk olanzapine associated highest placental exposure atypical despite available evidence suggests safe pregnancy although evidence insufficiently strong say anything high degree olanzapine associated weight gain according recent studies may put olanzapinetreated patients offspring heightened risk neural tube defects eg spina breastfeeding women taking olanzapine advised olanzapine secreted breast milk one study finding exposure infant citing increased risk stroke committee safety medicines uk issued warning olanzapine risperidone atypical antipsychotic medications given elderly patients dementia us olanzapine comes black box warning increased risk death elderly patients approved use patients dementiarelated bbc investigation june found advice widely ignored british evidence suggested elderly likely experience weight gain olanzapine compared aripiprazole principal side effect olanzapine weight gain may profound cases andor associated derangement bloodlipid bloodsugar profiles see section metabolic effects metaanalysis efficacy tolerance antipsychotic drugs apds found highest propensity causing weight gain apds compared smd extrapyramidal side effects although potentially serious infrequent rare may include tremors muscle rigidity aripiprazole asenapine clozapine quetiapine olanzapine comparison antipsychotic drugs less frequently associated hyperprolactinaemia although drugs cause transient sustained hyperprolactinaemia risk much lower owing partial dopaminergic agonist effect aripiprazole likely reduce prolactin levels patients cause although olanzapine causes early doserelated rise prolactin less frequent less marked seen haloperidol usually transient rise prolactin seen half patients olanzapine compared taking risperidone enduring increases less frequent taking recommended used im injection acute myocardial infarction bradycardia recent heart surgery severe hypotension sick sinus syndrome unstable several patient groups heightened risk side effects olanzapine antipsychotics general olanzapine may produce nontrivial high blood sugar people diabetes mellitus likewise elderly greater risk falls accidental injury young males appear heightened risk dystonic reactions although relatively rare olanzapine antipsychotics including olanzapine may disrupt bodys natural thermoregulatory systems thus permitting excursions dangerous levels situations exposure heat strenuous exercise side effects include galactorrhea amenorrhea gynecomastia erectile dysfunction many different types medication create induce pure obsessivecompulsive disorder ocd patients never symptoms new chapter ocd diagnostic statistical manual mental disorders fifth edition specifically includes druginduced ocd us food drug administration fda requires atypical antipsychotics include warning risk developing hyperglycemia diabetes factors metabolic syndrome effects may related drugs ability induce weight gain although reports made metabolic changes absence weight studies indicated olanzapine carries greater risk causing exacerbating diabetes another commonly prescribed atypical antipsychotic risperidone atypical antipsychotics olanzapine one likely induce weight gain based various effect dose dependent animal models olanzapineinduced metabolic side effects case reports olanzapineinduced diabetic olanzapine may decrease insulin though one study seems refute may also increase triglyceride despite weight gain large multicenter randomized national institute mental health study found olanzapine better controlling symptoms patients likely remain olanzapine one small openlabel nonrandomized study suggests taking olanzapine orally dissolving tablets may induce less weight substantiated blinded experimental setting postinjection deliriumsedation syndrome pdss rare syndrome specific longacting injectable formulation olanzapine olanzapine incidence pdss olanzapine pamoate estimated administrations unique among secondgeneration longacting antipsychotics eg paliperidone palmitate appear carry pdss characterized symptoms delirium eg confusion difficulty speaking uncoordinated movements people pdss exhibit delirium sedation although less specific pdss majority cases involved feeling general pdss may occur due accidental injection absorption olanzapine pamoate bloodstream act rapidly opposed slowly distributing muscle using proper intramuscularinjection technique olanzapine pamoate helps decrease risk pdss though eliminate fda advises people injected olanzapine pamoate watched hours administration event pdss olanzapine demonstrated carcinogenic effects multiple studies exposed chronically female mice rats male mice rats tumors found either liver mammary glands british national formulary recommends gradual withdrawal discontinuing antipsychotics avoid acute withdrawal syndrome rapid symptoms withdrawal commonly include nausea vomiting loss symptoms may include restlessness increased sweating trouble less commonly vertigo numbness muscle pains may symptoms generally resolve short tentative evidence indicates discontinuation antipsychotics result psychosis temporary withdrawal may also result reoccurrence condition rarely tardive dyskinesia occur medication symptoms overdose include tachycardia agitation dysarthria decreased consciousness coma death reported acute overdose mg also survival acute overdose fatalities generally occurred olanzapine plasma concentrations greater ngml post mortem concentrations ngml recorded though might represent confounding dead tissue may release olanzapine blood upon specific antidote olanzapine overdose known even physicians recommended call certified poison control center information treatment olanzapine considered moderately toxic overdose toxic quetiapine aripiprazole ssris less toxic monoamine oxidase inhibitors tricyclic drugs agents increase activity enzyme notably tobacco smoke may significantly increase hepatic firstpass clearance olanzapine conversely drugs inhibit activity examples ciprofloxacin fluvoxamine may reduce olanzapine carbamazepine known enzyme inducer decreased concentrationdose ration olanzapine compared olanzapine another enzyme inducer ritonavir also shown decrease bodys exposure olanzapine due induction enzymes uridine probenecid increases total exposure area curve maximum plasma concentration although olanzapines metabolism includes minor metabolic pathway presence inhibitor fluoxetine clinically significant effect olanzapines olanzapine first discovered searching chemical analog clozapine would require hematological monitoring investigation series thiophene isosteres phenyl rings clozapine thienobenzodiazepine analog olanzapine olanzapine higher affinity serotonin receptors dopamine receptors common property atypical antipsychotics aside benzamide antipsychotics amisulpride along nonbenzamides aripiprazole brexpiprazole blonanserin cariprazine melperone perospirone one study receptor occupancy lowdose olanzapine mgday occupancy high dose usual clinical dose range mgday receptor occupancy varied olanzapine occupancy receptor high doses mg mg reported mg dose olanzapine produced mean occupancy mg mg mg dose olanzapine highest affinity secondgeneration antipsychotic towards pglycoprotein one vitro pglycoprotein transports myriad drugs across number different biological membranes found numerous body systems including barrier semipermeable membrane filters contents blood prior reaching brain pgp inhibition could mean less brain exposure olanzapine results interaction relatively large quantity commonly encountered foods medications inhibit pgp pharmaceuticals fairly commonly either substrates pgp inhibit action substrates inhibitors pgp effectively increase permeability barrier pgp substrates subsequently increase central activity substrate reducing local effects gi tract mediation olanzapine central nervous system pgp means substance drug interacts pgp increases risk toxic accumulations olanzapine olanzapine potent antagonist muscarinic may underlie diabetogenic side additionally also exhibits relatively low affinity serotonin gabaa Î²adrenergic receptors benzodiazepine binding although antagonistic effects olanzapine alone associated weight gain olanzapine antagonism histaminergic muscarinic receptors implicated weight mode action olanzapines antipsychotic activity unknown may involve antagonism dopamine serotonin receptors antagonism dopamine receptors associated extrapyramidal effects tardive dyskinesia td therapeutic effects antagonism muscarinic acetylcholine receptors associated anticholinergic side effects dry mouth constipation addition may suppress reduce emergence extrapyramidal effects duration treatment offers protection development td common secondgeneration atypical antipsychotics olanzapine poses relatively low risk extrapyramidal side effects including td due higher affinity receptor antagonizing histamine receptors causes sedation may cause weight gain although antagonistic actions serotonin dopamine receptors also associated weight gain appetite olanzapine metabolized cytochrome cyp system principally isozyme lesser extent mechanisms oral dose average removed hepatic firstpass clearance olanzapine appears vary sex women roughly lower clearance clearance olanzapine also varies race selfidentified african americans blacks olanzapines clearance difference clearance apparent individuals identifying caucasian chinese routine pharmacokinetic monitoring olanzapine plasma levels generally unwarranted though unusual circumstances eg presence interactions desire determine patients taking medicine may prompt olanzapine unusual four wellcharacterised crystalline polymorphs many hydrated preparation olanzapine first disclosed series patents eli lilly co final two steps reduced stannous chloride ethanol give substituted thienobenzodiazepine ring system treated methylpiperazine mixture dimethyl sulfoxide toluene solvent produce olanzapine approved us fda drug became generic sales zyprexa billion us billion eli lilly faced many lawsuits people claimed developed diabetes diseases taking zyprexa well various governmental entities insurance companies others lilly produced large number documents part discovery phase litigation started documents ruled confidential judge placed seal later became subject lilly paid million settle around early lilly settled around suits million brought total lilly paid settle suits related drug december new york times article based leaked company documents concluded company engaged deliberate effort downplay olanzapines side company denied allegations stated article based cherrypicked documents provided times jim gottstein lawyer represented mentally ill patients obtained doctor david egilman serving expert consultant documents leaked online peertopeer filesharing networks hall others psychiatric survivors movement obtained lilly filed protection order stop dissemination documents judge jack b weinstein brooklyn federal district court granted judge weinstein also criticized new york times reporter gottstein egilman times london also received documents reported early lilly considered risk druginduced obesity top threat zyprexa october senior lilly research physician robert baker noted academic advisory board belonged quite impressed magnitude weight gain olanzapine implications lilly threatened egilman criminal contempt charges regarding documents took provided reporters september agreed pay lilly return companys agreement drop threat september judge weinstein issued order make public lillys internal documents drug different suit brought insurance companies pension funds march lilly settled suit state october lilly agreed pay million states district columbia settle suits brought state consumer protection eli lilly pleaded guilty us federal criminal misdemeanor charge illegally marketing zyprexa offlabel use agreed pay billion settlement announcement stated eli lilly admits september march company promoted zyprexa elderly populations treatment dementia including alzheimers dementia eli lilly agreed pay million criminal fine forfeit additional million outcomes described legal ramifications fueled motions appeals resolved gottstein summarized tangle legal activities impact political landscape psychiatry antipsychiatry us zyprexa olanzapine generic available many trade names olanzapine marketed number countries tablets ranging mg zyprexa generic olanzapine available orally disintegrating wafer rapidly dissolves saliva also available vials intramuscular olanzapine studied antiemetic particularly control chemotherapyinduced nausea vomiting general olanzapine appears effective aprepitant prevention cinv though concerns remain use population example concomitant use metoclopramide haloperidol increases risk extrapyramidal symptoms otherwise olanzapine appears fairly well tolerated indication somnolence common side olanzapine considered part early psychosis approach schizophrenia prevention risk identification management education study funded national institute mental health eli lilly tested hypothesis olanzapine might prevent onset psychosis people high risk schizophrenia study examined patients prodromal schizophrenia estimated risk developing schizophrenia within year treated half olanzapine half study patients receiving olanzapine significantly lower risk progressing psychosis vs olanzapine effective treating prodromal symptoms associated significant weight httpsenwikipediaorgwikiolanzapine